Skip to main content
Premium Trial:

Request an Annual Quote

Opko Partners with Bristol-Myers Squibb on Alzheimer's Blood Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Opko Health said today that it has entered into a collaboration agreement with Bristol-Myers Squibb to co-develop a blood test for Alzheimer's disease.

The company said that it will work with BMS to investigate the utility of its technology for diagnosis of Alzheimer's disease and for identifying individuals with early-stage cognitive impairment that are likely to progress to Alzheimer's disease.

As reported by GWDN's sister publication ProteoMonitor, Opko is developing an Alzheimer's diagnostic using a new technique for detecting disease-specific antibodies developed by researchers at the Scripps Research Institute in Jupiter, Fla.

The technique developed at Scripps uses synthetic molecules called peptoids to screen for autoantibodies in blood associated with Alzheimer's disease, Thomas Kodadek, professor of chemistry and cancer biology at Scripps and a scientific director at Opko, told ProteoMonitor.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.